Maryland is currently home to 2682 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Register for Updates
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
NCT04789044
Recruiting
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/17/2024
Locations: University of Maryland Medical Center Shock Trauma Center, Baltimore, Maryland
Conditions: Peripheral Nerve Injuries
Register for Updates
Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis
NCT03935295
Recruiting
This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport® and bracing, while the remaining patients will be treated with placebo and bracing.
Gender:
ALL
Ages:
Between 10 years and 16 years
Trial Updated:
12/17/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Adolescent Idiopathic Scoliosis
Register for Updates
A Study of Sovilnesib in Subjects with Ovarian Cancer
NCT06084416
Recruiting
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Register for Updates
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
NCT05642780
Recruiting
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Anne Arundel Medical Center (AAMC), Annapolis, Maryland
Conditions: Solid Tumor
Register for Updates
Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21
NCT05452902
Recruiting
Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of platinum-based chemotherapy, often used to treat gastrointestinal cancers. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to info... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University of Maryland Medical System, Baltimore, Maryland
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
NCT05301608
Recruiting
This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/16/2024
Locations: Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Conditions: Healthy
Register for Updates
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335
Recruiting
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/16/2024
Locations: Reviva site, Gaithersburg, Maryland
Conditions: Schizophrenia
Register for Updates
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT05154487
Recruiting
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Johns Hopkins Medicine, Baltimore, Maryland
Conditions: Endometroid Endometrial Cancer
Register for Updates
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
NCT04620759
Recruiting
The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
12/16/2024
Locations: Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Conditions: Major Depressive Disorder, Alcohol Use Disorder
Register for Updates
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
NCT04052022
Recruiting
Background: Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This is a paradoxical reaction. Researchers want to better understand what causes this reaction and what happens after someone has it. Objective: To learn about paradoxical reactions to TB treatment. Eligibility: Adults 18 and older diagnosed with confirmed or suspected TB and currently on treatment for at... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Tuberculosis
Register for Updates
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
NCT05364502
Recruiting
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Arterial Bleeding in Solid Organs and Peripheral Arteries
Register for Updates